Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.24.2.u1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating Activities:    
Net loss $ (14,955) $ (17,231)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 4] 114 113
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]] 2,742 2,275
Accrued interest on SVB convertible debt [note 7] 624 606
Accretion of discount on modification of debt 322 107
Change in fair value of contingent consideration [note 5 and note 6] 109  
Changes in operating assets and liabilities:    
Grant receivable [note 3] 111 (245)
Prepaid expenses and other assets 61 1,517
Accounts payable (68) (1,299)
Accrued liabilities other 266 369
Accrued clinical liabilities 1,428 (689)
Accrued compensation (962) (444)
Lease obligation [note 9] (1) (58)
Net cash used in operating activities (10,209) (14,979)
Financing Activities:    
Proceeds from exercise of warrants   227
Taxes paid related to net share settlement of equity awards (114) (220)
Net cash provided by financing activities 55,957 15,278
Investing Activities:    
Purchase of investments (46,568)  
Net cash used in investing activities (46,568)  
Effect of exchange rate changes on cash   1
Net increase/(decrease) in cash, cash equivalents and restricted cash (820) 300
Cash, cash equivalents and restricted cash at beginning of the period 15,596 24,821
Cash, cash equivalents and restricted cash at end of the period 14,776 25,121
November 2022 Private Placement [Member]    
Financing Activities:    
Financing costs relating to November 2022 private placement   (30)
May 2023 Private Placement [Member]    
Financing Activities:    
Proceeds from private placement, net of issuance costs   $ 15,301
February 2024 Private Placement [Member]    
Financing Activities:    
Proceeds from private placement, net of issuance costs $ 56,071